Albert Bourla is Pfizer’s Chief Executive Officer (CEO). As CEO, Albert leads Pfizer in its mission to be the world’s premiere biopharmaceutical company, bringing therapies to patients that improve their lives. These therapies include medicines, vaccines, and many of the world’s best-known consumer health care products.
Albert has over 25 years of proven leadership experience within Pfizer, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) since January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer ‘s Innovative Health, encompassing Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations, and ensuring broader business model innovation.
From January 2014 - January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology, and expanding the Company’s leadership in Vaccines.
From 2010-2013, Albert was President and General Manager of Pfizer’s Established Products business, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio (including legacy brands and generics).
Albert began his Pfizer career in the Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division. These included US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for Asia and Pacific.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. Albert is a member of the Pfizer Board of Directors, The Pfizer Foundation, and PhRMA.